Could a heart drug fix metabolism in black obesity?

NCT ID NCT06320951

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether vericiguat, a drug already used for heart failure, can improve how the body uses sugar and burns energy in Black adults with obesity and insulin resistance. Researchers will give 200 participants either vericiguat or a placebo daily for 12 weeks, measuring changes in insulin sensitivity and energy expenditure. The goal is to see if boosting a natural signaling pathway can lower the risk of heart disease and diabetes in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vericiguat (a drug that boosts a natural signaling pathway to improve metabolism)
What this could lead to
If it works, this could point toward a new way to reduce heart disease and diabetes risk in Black individuals with obesity.
What could go wrong
This is an early phase 2 trial with only 200 people over 12 weeks. It may not show clear benefits, and results may not apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.